{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:47:21Z","timestamp":1789696041681,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.euroneuro.2009.10.005","type":"journal-article","created":{"date-parts":[[2009,12,17]],"date-time":"2009-12-17T15:09:27Z","timestamp":1261062567000},"page":"80-87","source":"Crossref","is-referenced-by-count":53,"title":["Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder"],"prefix":"10.1016","volume":"20","author":[{"given":"Johannes","family":"Tauscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kielbasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Vandenhende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mozley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Gehlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Marek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2009.10.005_bib1","first-page":"331","article-title":"Gateways to clinical trials","volume":"27","author":"Bayes","year":"2005","journal-title":"Methods Find Exp. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0028-3908(99)00182-3","article-title":"Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey","volume":"39","author":"Bergstrom","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib3","series-title":"Brain Imaging Using PET","article-title":"NK1 receptor occupancy in the monkey brain studied by [11C]GR205171","author":"Bertoldo","year":"2002"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/da.10096","article-title":"Pharmacological treatment of social anxiety disorder: a meta-analysis","volume":"18","author":"Blanco","year":"2003","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.lfs.2005.04.075","article-title":"Use of LC\/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples","volume":"78","author":"Chernet","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1418.018","article-title":"Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry","volume":"1144","author":"Ebner","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biopsych.2005.03.029","article-title":"Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo","volume":"58","author":"Furmark","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0167-0115(96)00071-7","article-title":"GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity","volume":"65","author":"Gardner","year":"1996","journal-title":"Regul. Pept."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib10","series-title":"ECDEU Assessment Manual for Psychopharmacology \u2014 Revised (DHEW Publ No ADM 76-338)","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","article-title":"Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder","volume":"59","author":"Keller","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib13","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.npp.1300260","article-title":"Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression","volume":"29","author":"Kramer","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social phobia","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Mod. Probl. Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/jcbfm.1985.87","article-title":"Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations","volume":"5","author":"Patlak","year":"1985","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.1983.1","article-title":"Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data","volume":"3","author":"Patlak","year":"1983","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1109\/42.34710","article-title":"Interactive display and analysis of 3-D medical images","volume":"8","author":"Robb","year":"1989","journal-title":"IEEE Trans. Med. Imag."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0895-6111(89)90285-1","article-title":"Analyze: a comprehensive, operator-interactive software package for multidimensional medical image display and analysis","volume":"13","author":"Robb","year":"1989","journal-title":"Comput. Med. Imaging Graph."},{"key":"10.1016\/j.euroneuro.2009.10.005_bib20","series-title":"2000. Handbook of Psychiatric Measures. American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures","article-title":"Sheehan Disability Scale","author":"Sheehan","year":"1983"},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2009.10.005_bib23","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for Dsm-Iv and Icd-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.10.005_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0969-8051(01)00275-X","article-title":"Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach","volume":"29","author":"Zamuner","year":"2002","journal-title":"Nucl. Med. Biol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09002417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09002417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T13:20:34Z","timestamp":1544793634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X09002417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0924977X09002417"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.10.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}